New Product & Tech activity — 1 fresh signal just appeared.
The order this company entered each market — oldest to newest
Celltrion Focuses on Biosimilars, Not New Drugs
AWS · N. Virginia
Sign up to see the full signal feed
How Pinobio.com's international expansion compares to its competitors
Pinobio.comYouBars show relative size across the companies compared.
5 metrics| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Pinobio.comYou | 1 | 0 | +100% | 2 | 9 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
4 technologies detected across the stack.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
1 mention in the last 90 days.
Celltrion positions itself as a leading biosimilar company, not a new drug developer, and is expanding its R&D through ADC pipelines targeting verified therapeutic areas.
Pinobio leads a 22 billion won project to develop ADC production technology in Korea, collaborating with KBIOHEALTH, Kyongbo Pharm, and Nexa until 2028.
KBIOHEALTH participates in a national project to develop high-quality ADC production materials, components, and processes, collaborating with companies like Chong Kun Dang and Pino Bio.
Be the first to find verified contacts at Pinobio.com
Quick answers about Pinobio.com's business, markets, and growth signals.
“We reach accounts the week they land in-market — not the quarter after.”
Book a walkthrough of the movement map with our team.
Pubrio turns expansion signals across 200+ markets into one live graph, so revenue teams see which companies are entering new markets, and act on the timing.
© 2026 Pubrio. All rights reserved.
